Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone608-284-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$454.46 million
Profitability
Miscellaneous
Employees1,977
Next Earnings Date4/25/2019 (Estimated)
OptionableOptionable
EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions
What is EXACT Sciences' stock symbol?
EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."
How were EXACT Sciences' earnings last quarter?
EXACT Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Thursday, February, 21st. The medical research company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.05. The medical research company earned $142.98 million during the quarter, compared to analyst estimates of $143 million. EXACT Sciences had a negative net margin of 38.54% and a negative return on equity of 23.58%. EXACT Sciences's revenue for the quarter was up 63.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.18) EPS. View EXACT Sciences' Earnings History.
When is EXACT Sciences' next earnings date?
What guidance has EXACT Sciences issued on next quarter's earnings?
EXACT Sciences updated its FY 2019 earnings guidance on Thursday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $710-730 million, compared to the consensus revenue estimate of $704.35 million.
What price target have analysts set for EXAS?
12 equities research analysts have issued 1-year target prices for EXACT Sciences' stock. Their forecasts range from $84.00 to $120.00. On average, they anticipate EXACT Sciences' stock price to reach $99.70 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price. View Analyst Price Targets for EXACT Sciences.
What is the consensus analysts' recommendation for EXACT Sciences?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.
Has EXACT Sciences been receiving favorable news coverage?
News headlines about EXAS stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. EXACT Sciences earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of EXACT Sciences' key competitors?
Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Exelixis (EXEL), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of EXACT Sciences own?
Who are EXACT Sciences' key executives?
EXACT Sciences' management team includes the folowing people:
- Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
- Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
- Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
- Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
- Ms. Ana Hooker, Sr. VP of Operations
Who are EXACT Sciences' major shareholders?
EXACT Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.00%), Geode Capital Management LLC (0.97%), Geode Capital Management LLC (0.97%), Norges Bank (0.87%), Jennison Associates LLC (0.85%) and Eagle Asset Management Inc. (0.81%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.
Which institutional investors are selling EXACT Sciences stock?
EXAS stock was sold by a variety of institutional investors in the last quarter, including GABELLI & Co INVESTMENT ADVISERS INC., Frontier Capital Management Co. LLC, KAMES CAPITAL plc, Eagle Asset Management Inc., Victory Capital Management Inc., CIBC Private Wealth Group LLC, Macquarie Group Ltd. and Kornitzer Capital Management Inc. KS. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.
Which institutional investors are buying EXACT Sciences stock?
EXAS stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Eaton Vance Management, First Trust Advisors LP, Intrinsic Edge Capital Management LLC, Geode Capital Management LLC, Geode Capital Management LLC, R.H. Dinel Investment Counsel Inc. and Foresters Investment Management Company Inc.. View Insider Buying and Selling for EXACT Sciences.
How do I buy shares of EXACT Sciences?
Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EXACT Sciences' stock price today?
One share of EXAS stock can currently be purchased for approximately $89.00.
How big of a company is EXACT Sciences?
EXACT Sciences has a market capitalization of $11.19 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.
What is EXACT Sciences' official website?
How can I contact EXACT Sciences?
EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.
MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
